Compare ANVS & RBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANVS | RBOT |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 17.0M |
| IPO Year | 2020 | N/A |
| Metric | ANVS | RBOT |
|---|---|---|
| Price | $3.95 | $2.56 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $13.50 | $7.00 |
| AVG Volume (30 Days) | ★ 1.8M | 156.6K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $2.36 |
| 52 Week High | $5.60 | $18.97 |
| Indicator | ANVS | RBOT |
|---|---|---|
| Relative Strength Index (RSI) | 52.44 | 32.94 |
| Support Level | $4.12 | $2.36 |
| Resistance Level | $4.24 | $3.07 |
| Average True Range (ATR) | 0.47 | 0.34 |
| MACD | -0.15 | 0.06 |
| Stochastic Oscillator | 11.67 | 4.45 |
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port. The company has following segment: Research and development, Sales and marketing, General and administrative.